Cell Death and Disease (May 2024)

Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome

  • Filippo Consonni,
  • Solange Moreno,
  • Blanca Vinuales Colell,
  • Marie-Claude Stolzenberg,
  • Alicia Fernandes,
  • Mélanie Parisot,
  • Cécile Masson,
  • Nathalie Neveux,
  • Jérémie Rosain,
  • Sarah Bamberger,
  • Marie-Gabrielle Vigue,
  • Marion Malphettes,
  • Pierre Quartier,
  • Capucine Picard,
  • Frédéric Rieux-Laucat,
  • Aude Magerus

DOI
https://doi.org/10.1038/s41419-024-06679-6
Journal volume & issue
Vol. 15, no. 5
pp. 1 – 8

Abstract

Read online

Abstract Autoimmune lymphoproliferative syndrome (ALPS) is a primary disorder of lymphocyte homeostasis, leading to chronic lymphoproliferation, autoimmune cytopenia, and increased risk of lymphoma. The genetic landscape of ALPS includes mutations in FAS, FASLG, and FADD, all associated with apoptosis deficiency, while the role of CASP10 defect in the disease remains debated. In this study, we aimed to assess the impact of CASP10 variants on ALPS pathogenesis. We benefit from thousands of genetic analysis datasets performed in our Institute’s genetic platform to identify individuals carrying CASP10 variants previously suspected to be involved in ALPS outcome: p.C401LfsX15, p.V410I and p.Y446C, both at heterozygous and homozygous state. Clinical and laboratory features of the six included subjects were variable but not consistent with ALPS. Two individuals were healthy. Comprehensive analyses of CASP10 protein expression and FAS-mediated apoptosis were conducted and compared to healthy controls and ALPS patients with FAS mutations. Missense CASP10 variants (p.V410I and p.Y446C), which are common in the general population, did not disrupt CASP10 expression, nor FAS-mediated apoptosis. In contrast, homozygous p.C401LfsX15 CASP10 variant lead to a complete abolished CASP10 expression but had no impact on FAS-mediated apoptosis function. At heterozygous state, this p.C401LfsX15 variant lead to a reduced CASP10 protein levels but remained associated with a normal FAS-mediated apoptosis function. These findings demonstrate that CASPASE 10 is dispensable for FAS-mediated apoptosis. In consequences, CASP10 defect unlikely contribute to ALPS pathogenesis, since they did not result in an impairment of FAS-mediated apoptosis nor in clinical features of ALPS in human. Moreover, the absence of FAS expression up-regulation in subjects with CASP10 variants rule out any compensatory mechanisms possibly involved in the normal apoptosis function observed. In conclusion, this study challenges the notion that CASP10 variants contribute to the development of ALPS.